alpha-1 proteinase inhibitor, Prolastin-C

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical Editor: Charles Patrick Davis, MD, PhD
    Charles Patrick Davis, MD, PhD

    Charles Patrick Davis, MD, PhD

    Dr. Charles "Pat" Davis, MD, PhD, is a board certified Emergency Medicine doctor who currently practices as a consultant and staff member for hospitals. He has a PhD in Microbiology (UT at Austin), and the MD (Univ. Texas Medical Branch, Galveston). He is a Clinical Professor (retired) in the Division of Emergency Medicine, UT Health Science Center at San Antonio, and has been the Chief of Emergency Medicine at UT Medical Branch and at UTHSCSA with over 250 publications.

Understanding COPD

SIDE EFFECTS: The most common side effects of alpha-1 proteinase inhibitor are:



PREPARATIONS: Alpha-1 proteinase inhibitor is available in a kit containing a single-use vial of 1000 mg alpha-1 proteinase inhibitor as a lyophilized powder, one 20 ml vial of sterile water for dilution, a transfer needle, and a filter needle.

STORAGE: Alpha-1 proteinase inhibitor should be stored below 25 C (77 F). This medicine does not require refrigeration and should not be stored in the freezer. After mixing, the solution can be kept at room temperature for administration within 3 hours.

DOSING: The recommended dose of alpha-1 proteinase inhibitor is 60 mg/kg administered into the vein (intravenously) once weekly. Alpha-1 proteinase inhibitor should be administered at a rate of up to 0.08 milliliters for each kilogram per minute. On average, each infusion takes about 15 minutes.

Patients, family members, or caregivers can be trained to administer alpha1-proteinase inhibitor at home.

DRUG INTERACTIONS: Information on drug-drug interaction is not found in the medical literature and is not provided by the manufacturer.

PREGNANCY: Alpha-1 proteinase inhibitor has not been adequately evaluated in pregnant women. Due to the lack of conclusive safety data, alpha-1 proteinase inhibitor should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Alpha-1 proteinase inhibitor is classified as FDA pregnancy risk category C.

NURSING MOTHERS: It is not known if alpha-1 proteinase inhibitor is excreted in breast milk. Because many drugs enter human milk and can potentially cause harm to the nursing infant, alpha-1 proteinase inhibitor should be used cautiously in nursing mothers.

REFERENCE: FDA Prescribing Information

Medically Reviewed by a Doctor on 3/20/2015

Quick GuideCOPD Lung Symptoms, Diagnosis, Treatment

COPD Lung Symptoms, Diagnosis, Treatment
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Allergy and Asthma Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors